Optimizing Medical Affairs’ Role in Cardiology & Pulmonology Launches

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Medical Affairs Product Launch in Cardiology and Pulmonology: Roles, Collaboration, and Evolution”

STUDY OVERVIEW

Medical Affairs can significantly boost the success of Cardiology and Pulmonology product launches by redefining their roles, activities, and strategies. This involves a range of high-impact programs and necessitates collaboration with various internal teams, underscoring the complexity and importance of these therapeutic fields.

Best Practices, LLC conducted this benchmarking research to investigate the evolving role of Medical Affairs in Cardiology and Pulmonology product launches. The study examines the effectiveness of medical leadership roles, the importance of cross-functional alignment, and the ongoing adaptation to changes within the medical landscape. By providing insights into these critical areas, the research aims to enhance understanding of how Medical Affairs can drive success in launching cardiology and pulmonology products.

KEY TOPICS

Medical Leadership Roles and Launch Activity Effectiveness in Cardiology and Pulmonology
Ensuring Cross-functional Alignment and Collaboration in Cardiology and Pulmonology Launches
Adopting to Ongoing Changes in Medical Landscape

KEY METRICS

Medical Affairs’ role in Cardiology and Pulmonology launches
Effective Medical Affairs launch activities in Cardiology and Pulmonology segment
Improvement areas for Medical Affairs around Cardiology and Pulmonology launches
Medical Affairs’ internal collaboration to ensure successful Cardiology and Pulmonology launches
Medical Affairs’ cross-functional team role

SAMPLE KEY FINDINGS

Internal Group Collaboration: Medical collaborates early and often with cross-functional launch teams (82%) through clearly defined roles, responsibilities, and expectations (65%) to ensure successful Cardiology and Pulmonology launches.

METHODOLOGY

This benchmarking study engaged 19 Medical leaders from 15 leading life sciences organizations. The study insights are drawn primarily from Medical Directors and VPs, representing nearly 80% of the benchmark class.

Industries Profiled:
Pharmaceutical; Diagnostic; Biotech; Chemical; Health Care; Biopharmaceutical; Consulting; Consumer Products; Science

Companies Profiled:
AstraZeneca; BIAL; bioMerieux; Boehringer Ingelheim; Cardinal Health; Eurofarma; Genentech; Labaid Group; Matinas BioPharma; MEDiSTRAVA; Merck KGaA; Novartis; Pixacore; Pfizer; Thermo Fisher Scientific

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Medical Affairs Product Launch in Cardiology and Pulmonology: Roles, Collaboration, and Evolution

ID: 5814

Features:

Pages/Slides: 31

Published: 2024

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
690D2C708D3F739DE00258B5E002C8FB0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-product-launch-in-cardiology-pulmonology-roles-collaboration-evolution?opendocument
18
19opendocument
203.238.82.77
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB